Current Research Studies - Heart & Vascular

The following list contains clinical studies in which the OSF HealthCare Cardiovascular Institute is enrolling patients.

For questions or to enroll, please contact our research staff at (309) 589-1930 in the Peoria area and (815) 395-9181 in Rockford.

Peoria Area

  • PRESERVED HF - Effects of dapagliflozin on biomarkers, symptoms and functional status in patients with Type 2 diabetes or pre-diabetes, and PRESERVED ejection fraction Heart Failure

  • Summary: A study to evaluate the effects of Dapagliflozin on biomarkers, symptoms and functional status in patients with Type II Diabetes or pre-diabetes, and preserved Ejection Fraction Heart Failure.

    Investigator: Barry Clemson

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    ClinicalTrials.gov: NCT03030235

    Contact: Stephanie Hillis, (309) 589-1934, stephanie.j.hillis@osfhealthcare.org

  • A-DUE - Prospective, multi-center, double-blind, randomized, active-controlled, triple-dummy, parallel-group, group sequential, adaptive Phase 3 clinical study to compare the efficacy and safety of macitentan, and tadalafil monotherapies with the corresponding fixed dose combination in subjects with pulmonary arterial hypertension (PAH), followed by an open-label treatment period with macitentan and tadalafil fixed dose combination therapy

  • Summary: Combination therapy in pulmonary arterial hypertension (PAH) has been the subject of active investigation for more than a decade, with the benefit of targeting different pathways known to be involved in the pathogenesis of the disease. Adherence to prescribed therapy has an impact on clinical outcomes. Reducing the pill/tablet count and frequency has a major impact on patients' adherence to therapies and therefore the observed clinical outcomes. One way to simplify treatment is to use fixed-dose combination (FDC) products that combine multiple treatments targeting different pathways into a single tablet.

    This study aims to demonstrate that the FDC of macitentan and tadalafil is more effective than therapy with 10 mg of macitentan alone or 40 mg of tadalafil alone. This phase 3 study will evaluate the efficacy and safety at 16 weeks of an FDC (macitentan 10 mg and tadalafil 40 mg) against these two PAH-approved therapies given as monotherapy to further confirm the added value of the FDC.

    Investigator: Chetan Bhardwaj

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    ClinicalTrials.gov: NCT03904693

    Contact: Stephanie Hillis, (309) 589-1930

  • AEGIS II - A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL 112 in Subjects with Acute Coronary Syndrome

  • Summary: This is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI), including those managed with percutaneous coronary intervention (PCI) or medically managed.

    Investigator: Tinoy Kizhakekuttu

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    ClinicalTrials.gov: NCT03473223

    Contact: Stephanie Hillis, (309) 589-1930

  • PARAGLIDE HF - A Multicenter, randomized, double-blind, double-dummy, parallel group, active controlled 8 week study to evaluate the effect of sacubitril/valsartan (LCZ696) versus valsartan on changes in NT-proBNP and safely tolerability of in-hospital initiation of LCZ696 compared to valsartan in HFpEF patients with acute decompensated heart failure (ADHF) who have been stabilized during hospitalization

  • Summary: The purpose of this study is to assess the effect of sacubitril/valsartan (LCZ696) vs. valsartan on changes in NT-proBNP and outcomes, safety and tolerability in patients with HFpEF (left ventricular ejection fraction (LVEF) > 40%) who have been stabilized during hospitalization for acute decompensated heart failure and initiated in-hospital or within 30 days post discharge.

    Investigator: Chetan Bhardwaj

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    ClinicalTrials.gov: NCT03988634

    Contact: Stephanie Hillis, (309) 589-1930

  • PROACTIVE HF - A Prospective, Multi-Center, Randomized, Controlled, Single Blind Clinical Trial Evaluating the Safety and Efficacy of the Cordella™ Pulmonary Artery Sensor System in New York Heart Association (NYHA) Class III Heart Failure Patients

  • Summary: This is a prospective, randomized, controlled, single blind, multicenter clinical trial to evaluate the safety and effectiveness of the Cordella PA Sensor System in NYHA Class III Heart Failure Patients

    Investigator: Christopher Sparrow

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    ClinicalTrials.gov: NCT04089059

    Contact: Stephanie Hillis, (309) 589-1930

  • DIAMOND - A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone

  • Summary: The purpose of this study is to determine if patiromer treatment of subjects who developed hyperkalemia while receiving RAASi medications will result in continued use of RAASi medications in accordance with heart failure (HF) treatment guidelines and thereby decrease the occurrence of the combined endpoint of cardiovascular (CV) death and CV hospitalization events compared with placebo treatment.

    Investigator: Chetan Bhardwaj

    Location: OSF HealthCare Cardiovascular Institute, Peoria, Illinois

    ClinicalTrials.gov: NCT03888066

    Contact: Stephanie Hillis, (309) 589-1930